MiMedx Group, Inc. (NASDAQ:MDXG) Receives $12.00 Consensus Target Price from Analysts

Shares of MiMedx Group, Inc. (NASDAQ:MDXG) have been assigned an average rating of “Buy” from the five analysts that are covering the firm, MarketBeat Ratings reports. Five analysts have rated the stock with a buy recommendation. The average 1 year price target among analysts that have covered the stock in the last year is $12.00.

Separately, StockNews.com downgraded shares of MiMedx Group from a “strong-buy” rating to a “buy” rating in a report on Friday, November 8th.

MiMedx Group Trading Down 2.4 %

NASDAQ:MDXG opened at $8.70 on Friday. The firm has a market capitalization of $1.28 billion, a P/E ratio of 15.82 and a beta of 1.96. The business has a 50 day simple moving average of $9.18 and a 200 day simple moving average of $7.53. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.10 and a quick ratio of 3.53. MiMedx Group has a 12-month low of $5.47 and a 12-month high of $10.14.

MiMedx Group (NASDAQ:MDXG) last released its quarterly earnings results on Wednesday, October 30th. The company reported $0.07 EPS for the quarter, topping the consensus estimate of $0.05 by $0.02. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. The business had revenue of $84.06 million during the quarter, compared to analyst estimates of $81.00 million. During the same quarter in the prior year, the firm earned $0.05 earnings per share. Equities research analysts predict that MiMedx Group will post 0.3 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Van ECK Associates Corp acquired a new stake in MiMedx Group during the 4th quarter valued at $40,000. Blue Trust Inc. acquired a new stake in shares of MiMedx Group in the third quarter valued at $30,000. Point72 Asset Management L.P. bought a new position in shares of MiMedx Group in the second quarter valued at about $40,000. Point72 DIFC Ltd lifted its position in MiMedx Group by 127.6% during the 3rd quarter. Point72 DIFC Ltd now owns 7,626 shares of the company’s stock worth $45,000 after buying an additional 4,275 shares in the last quarter. Finally, Savant Capital LLC bought a new stake in MiMedx Group during the 4th quarter worth about $100,000. 79.15% of the stock is currently owned by institutional investors and hedge funds.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.